Cargando…

Multi-Targeted Antiangiogenic Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer: Meta-Analyses of 20 Randomized Controlled Trials and Subgroup Analyses

BACKGROUND: Multi-targeted antiangiogenic tyrosine kinase inhibitors (MATKIs) have been studied in many randomized controlled trials (RCTs) for treatment of advanced non-small cell lung cancer (NSCLC). We seek to summarize the most up-to-date evidences and perform a timely meta-analysis. METHODS: El...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Wenhua, Wu, Xuan, Hong, Shaodong, Zhang, Yaxiong, Kang, Shiyang, Fang, Wenfeng, Qin, Tao, Huang, Yan, Zhao, Hongyun, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199622/ https://www.ncbi.nlm.nih.gov/pubmed/25329056 http://dx.doi.org/10.1371/journal.pone.0109757

Ejemplares similares

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
por: Ribatti, Domenico
Publicado: (2010)

The Efficacy of Combining Antiangiogenic Agents with Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer Who Failed First-Line Chemotherapy: A Systematic Review and Meta-Analysis
por: Sheng, Jin, et al.
Publicado: (2015)

Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials
por: Hong, Shaodong, et al.
Publicado: (2014)

Design and profile of low-molecular-weight receptor tyrosine kinase inhibitors for antiangiogenic therapy
por: Wood, JM
Publicado: (2001)

Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
por: Zhang, Yaxiong, et al.
Publicado: (2014)

Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity
por: Rovithi, Maria, et al.
Publicado: (2017)

Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors
por: Centanni, Maddalena, et al.
Publicado: (2022)

The Outcome of Discontinuing Tyrosine Kinase Inhibitors in Advanced Sarcoma Following a Favorable Tumor Response to Antiangiogenics Therapy
por: Zhang, Zhusheng, et al.
Publicado: (2022)

PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
por: Stokes, Michael E., et al.
Publicado: (2023)

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model
por: Diaz, Roque, et al.
Publicado: (2010)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Case of Tracheoesophageal Fistula Formation as a Rare Complication of Antiangiogenic Tyrosine Kinase Inhibitor Therapy for Metastatic Hepatocellular Carcinoma
por: Adeoye, Oluwatayo, et al.
Publicado: (2023)

Inconsistency between overall and subgroup analyses
por: Wang, Hongyue, et al.
Publicado: (2022)

Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China
por: Fang, Wenfeng, et al.
Publicado: (2019)

Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review
por: Walraven, Maudy, et al.
Publicado: (2010)

The lack of statistical power of subgroup analyses in meta-analyses: a cautionary note
por: Cuijpers, Pim, et al.
Publicado: (2021)

Identification of 20(S)-Ginsenoside Rh2 as a Potential EGFR Tyrosine Kinase Inhibitor
por: Liang, Yuan, et al.
Publicado: (2022)

MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis
por: Fang, Wenfeng, et al.
Publicado: (2020)

Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison
por: Wang, Chen, et al.
Publicado: (2016)

Challenges and Solutions to Pre- and Post-Randomization Subgroup Analyses
por: Desai, Manisha, et al.
Publicado: (2014)

Absolute vs. relative effects—implications for subgroup analyses
por: Andersen, Lars W.
Publicado: (2021)

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
por: Huang, Liling, et al.
Publicado: (2020)

Genome-wide expression and methylation analyses reveal aberrant cell adhesion signaling in tyrosine kinase inhibitor-resistant CML cells
por: Kaehler, Meike, et al.
Publicado: (2022)

Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy
por: Xu, Wenjing, et al.
Publicado: (2022)

Discovery of multi-target receptor tyrosine kinase inhibitors as novel anti-angiogenesis agents
por: Wang, Jinfeng, et al.
Publicado: (2017)

Cost-effectiveness and value of information analyses of Bruton’s tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States
por: Alrawashdh, Neda, et al.
Publicado: (2022)

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
por: Fang, Wenfeng, et al.
Publicado: (2014)

Improved Glycemic Control With the Multi-Receptor Tyrosine Kinase Inhibitor Pazopanib
por: Böhm, Steffen, et al.
Publicado: (2010)

Empirically derived phenotypic subgroups – qualitative and quantitative trait analyses
por: Wilcox, Marsha A, et al.
Publicado: (2003)

Three simple rules to ensure reasonably credible subgroup analyses
por: Burke, James F, et al.
Publicado: (2015)

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study
por: Vogelmeier, Claus F, et al.
Publicado: (2018)

A critical review of graphics for subgroup analyses in clinical trials
por: Ballarini, Nicolás M., et al.
Publicado: (2020)

Concerns about subgroup analyses and reason for stopping remdesivir trial
por: Vijayaraghavan, Bharath Kumar Tirupakuzhi
Publicado: (2022)

Evaluating sensitivity to classification uncertainty in latent subgroup effect analyses
por: Loh, Wen Wei, et al.
Publicado: (2022)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors
por: Mantia, Charlene M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fklcmjn2ro7h67so8mlrkvd34e